Source: International Congress 2015 – Sarcoidosis: pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Daniëlle Hijdra (Nieuwegein, Netherlands), Adriane Vorselaars, Daniëlle Hijdra, Heleen Crommelin, Coline Van Moorsel, Jan Grutters. Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis. Eur Respir J 2015; 46: Suppl. 59, 3312

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Are there any predictors of MTX response in progressive pulmonary sarcoidosis? Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Relapse after discontinuation of infliximab in sarcoidosis patients can be predicted by PET-scan and sIL-2R Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 Immunosuppressive treatment is not a predictor of mortality after surgical lung biopsy for interstitial lung disease Source: International Congress 2016 – Sarcoidosis Year: 2016